| 3.59 0 (0%) | 03-20 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.49 | 1-year : | 5.23 |
| Resists | First : | 3.84 | Second : | 4.47 |
| Pivot price | 3.72 |
|||
| Supports | First : | 2.81 | Second : | 2.34 |
| MAs | MA(5) : | 3.76 |
MA(20) : | 3.6 |
| MA(100) : | 2.73 |
MA(250) : | 2.2 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 44 |
D(3) : | 52.1 |
| RSI | RSI(14): 53.5 | |||
| 52-week | High : | 4.47 | Low : | 1.38 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ WHWK ] has closed above bottom band by 37.8%. Bollinger Bands are 89.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 15 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 3.67 - 3.69 | 3.69 - 3.7 |
| Low: | 3.35 - 3.37 | 3.37 - 3.4 |
| Close: | 3.55 - 3.59 | 3.59 - 3.63 |
Whitehawk Therapeutics Inc operates as a clinical-stage biopharmaceutical company. The Company develops precision therapies for genetically-defined cancers.
Tue, 17 Mar 2026
Inside Whitehawk's 3 next-gen cancer drug conjugates debuting at AACR 2026 - Stock Titan
Tue, 17 Mar 2026
Whitehawk Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary - TradingView
Sat, 14 Mar 2026
Suvretta Capital Management LLC Buys Shares of 3,700,000 Whitehawk Therapeutics, Inc. $WHWK - MarketBeat
Fri, 13 Mar 2026
Whitehawk Therapeutics Inc expected to post a loss of 6 cents a share - Earnings Preview - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 47 (M) |
| Shares Float | 19 (M) |
| Held by Insiders | 12.4 (%) |
| Held by Institutions | 76.1 (%) |
| Shares Short | 777 (K) |
| Shares Short P.Month | 781 (K) |
| EPS | -0.64 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.33 |
| Profit Margin | -108.6 % |
| Operating Margin | -754.1 % |
| Return on Assets (ttm) | -53.7 % |
| Return on Equity (ttm) | -13.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -1.56 |
| Sales Per Share | 0.3 |
| EBITDA (p.s.) | -2.3 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -95 (M) |
| Levered Free Cash Flow | -52 (M) |
| PE Ratio | -5.61 |
| PEG Ratio | 0 |
| Price to Book value | 1.07 |
| Price to Sales | 11.76 |
| Price to Cash Flow | -1.78 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|